International grant powers new AI breakthroughs in ovarian cancer at WIMR

We’re incredibly grateful for the remarkable support provided by the Ovarian Cancer Research Foundation, and their partners in the Global Ovarian Cancer Research Consortium, Ovarian Cancer Research Alliance (United States), Ovarian Cancer Canada, and Ovarian Cancer Action (United Kingdom) through their AI Accelerator Grant.

This investment is a powerful boost for our Australian team at the Westmead Institute for Medical Research, Peter MacCallum Cancer Centre, QIMR Berghofer Medical Research Institute and UNSW and an exciting moment for ovarian cancer research globally. With access to advanced AI capability and one of the world’s most comprehensive ovarian cancer datasets, this grant enables researchers to uncover new insights that could transform how we predict treatment response, personalise care, and ultimately improve survival outcomes for women everywhere.

This work has never been more important. Ovarian cancer remains one of the most lethal gynaecological cancers with around 2,000 Australians diagnosed each year, and nearly 1,000 lives lost annually, with a five‑year survival rate of just 49%. Symptoms are often vague, leading many to be diagnosed late. The urgent need for innovation is clear, and this grant represents a major step forward. We’re proud to be part of a global effort working toward better tools, better treatments, and better futures for everyone impacted by ovarian cancer.